Published • loading... • Updated
New lung cancer drug adds nearly six months of survival; stomach cancer treatment dou
The studies showed improved survival and fewer severe side effects, but both drugs remain investigational and need regulatory approval before routine use.
Summary by Ynet News
4 Articles
4 Articles
New lung cancer drug adds nearly six months of survival; stomach cancer treatment dou
Two Phase 3 trials presented at Europe's leading oncology conference show major survival gains: Roche's divarasib outperforms existing targeted lung cancer drugs, while AstraZeneca's experimental therapy doubles median survival for certain advanced stomach cancer patients; neither has yet been approved for routine use
·Tel Aviv-Yafo, Israel
Read Full Article
The Congress of the European Society of Medical Oncology held in Madrid until 27 October marks a decisive therapeutic breakthrough against lung cancer with the presentation of two new treatments.
A new drug for stomach cancer may double survival in patients with advanced or metastatic disease, according to a new study.
Coverage Details
Total News Sources4
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
